News | June 15, 2010

Trial Finds Aneurysm Size Does Not Affect Outcome After EVAR

June 15, 2010 – Patients with smaller abdominal aortic aneurysms (AAAs) (less than 5.5 cm) have no significant differences in clinical outcomes after endovascular repair (EVAR) than those with larger AAAs according to data from a five-year prospective clinical trial setting. The researchers maintain their recommendation that small aneurysms should not be treated surgically. Details of this study were presented at the 64th Vascular Annual Meeting hosted the Society for Vascular Surgery.

Researchers from the Washington University School of Medicine in St. Louis reported data from a subgroup analysis of the prospective Medtronic Talent Enhanced Low Profile System trial. There were no statistically significant differences in the rate of freedom from major adverse events (84.6 percent versus 75.8 percent) or freedom from aneurysm-related mortality (98.7 percent versus 96.8 percent) at one year. Long-term outcomes at five years also showed no difference.

Jeffrey Jim, M.D., a fellow from the section of vascular surgery, said that 156 patients enrolled in the prospective Medtronic Talent Enhanced Low Profile System trial were evaluated. Analyses were performed for patients with AAAs that measured less than 5.5 cm and for those with AAAs larger than 5.5 cm. Demographics, aneurysm morphology, and perioperative endpoints were assessed. Safety and effectiveness endpoints were evaluated at 30 days, one year, and five years after the procedures.

"All patients in the study (85 small AAAs and 71 large) had similar age, gender and medical risk profile," Jim said. "However, there were anatomic differences between the two group with the aortic neck in small AAA patients being longer (24.7 mm vs 20.7 mm), less angulated (27.20 vs 34.20) and smaller (24.6 mm vs 26.1 mm). In terms of perioperative outcomes, the two groups were very similar with the only difference being the small AAA patients spent less time in the intensive care unit (8.1 hours vs 26.3 hours). The small AAA patients also had higher rate of successful aneurysm treatment at 12 months (96.8 vs 84.9 percent) as defined by the study as the combination of technical success, absence of aneurysm expansion, and absence of reintervention for type I or type III endoleaks."

Jim added that there were no other statistically significant differences during the perioperative period or any other effectiveness endpoints at 12 months. There were also no differences in rates of migration, endoleaks, change in aneurysm diameter or freedom from aneurysm-related mortality at five years.

"We even did further subgroup analyses by separating groups by AAA centimeter size: 55 patients with very small (less than 5 cm), 30 with small (5.1-5.4 cm), and 71 with larger (more than 5.5 cm). The findings were similar to our original comparison," Jim said. "The data from this study is unique in that it comes from a prospective five-year clinical trial. The results confirm the intuitive notion that smaller AAAs have aortic neck characteristics that are more favorable for EVAR. However, the important take home message is that there were no differences in long-term five-year outcomes between the two groups. So our position remains that EVAR should not be routinely recommended for those with small AAAs."

For more information:

Related Content

Biotronik Studies Demonstrate Efficacy of Minimizing Metal Burden in SFA Therapy
News | Stents Bare Metal| September 22, 2017
Physicians demonstrated that reducing metal burden in superficial femoral artery (SFA) therapy could effectively reduce...
Edwards Inspiris Resilia Valve Receives FDA Approval
News | Heart Valve Technology| September 21, 2017
Edwards Lifesciences Corp. recently received U.S. Food and Drug Administration (FDA) approval for its Inspiris Resilia...
MyoKardia Presents Additional Positive Data From Phase 2 PIONEER-HCM Study at HFSA 2017
News | Heart Failure| September 21, 2017
MyoKardia Inc. announced that additional positive data from the first patient cohort of its Phase 2 PIONEER-HCM study...
DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD)| September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Marijuana Associated With Three-Fold Risk of Death From Hypertension
News | Hypertension| September 14, 2017
Marijuana use is associated with a three-fold risk of death from hypertension, according to research published recently...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Medtronic Announces Japanese Regulatory Approval for In.Pact Admiral Drug-Coated Balloon
News | Drug-Eluting Balloons| September 13, 2017
Medtronic plc announced that the In.Pact Admiral Drug-Coated Balloon (DCB) received approval from the Japanese Ministry...
Overlay Init